An attempt to generate an antitumor effect in the regional lymph nodes against endometrial cancer cells by inducing antitumor cytokines.

[1]  G. Forni,et al.  Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. , 1994, British Journal of Cancer.

[2]  B. Corn,et al.  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence , 1993, Cancer.

[3]  T. Gatanaga,et al.  Growth of the endometrial adenocarcinoma cell line AN3 CA is modulated by tumor necrosis factor and its receptor is up-regulated by estrogen in vitro. , 1992, Endocrinology.

[4]  C. Carrasco,et al.  Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases , 1992, Cancer.

[5]  D. Morton,et al.  Interleukin 4 Alone and with γ-Interferon or α-Tumor Necrosis Factor Inhibits Cell Growth and Modulates Cell Surface Antigens on Human Renal Cell Carcinomas , 1991 .

[6]  T. Iwasaka,et al.  Antitumor effects of human recombinant interferon-gamma and tumor necrosis factor on five cervical adenocarcinoma cell lines, in vivo and in vitro. , 1991, Gynecologic oncology.

[7]  W. Benjamin,et al.  Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3). , 1991, Cancer research.

[8]  P. Fisher,et al.  Intratumor administration of beta‐interferon in recurrent malignant gliomas. A phase I clinical and laboratory study , 1990, Cancer.

[9]  C. Bucana,et al.  Augmentation of antiproliferative activity of interferon alfa against human bladder tumor cell lines by encapsulation of interferon alfa within liposomes. , 1989, Journal of the National Cancer Institute.

[10]  D. Spriggs,et al.  Tumor necrosis factor: still a promising agent. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Forni,et al.  Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of lnterleukin‐2 injected periiymphatically , 1988, Cancer.

[12]  C. Slingluff,et al.  Autologous lymph node cell‐derived tumor‐specific cytotoxic t‐cells for use in adoptive immunotherapy of human melanoma , 1988, Cancer.

[13]  K. Sugimachi,et al.  Antitumor activity of regional lymph node lymphocytes in patients with lung cancer , 1988, Journal of surgical oncology.

[14]  J. Willson,et al.  Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines. , 1987, Cancer research.

[15]  M. Berens,et al.  Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. , 1986, Cancer research.

[16]  J. Bellanti,et al.  In vitro synergism between interferons and human lymphotoxin: enhancement of lymphotoxin-induced target cell killing. , 1983, Journal of immunology.